Mutual of America Capital Management LLC Makes New $3.04 Million Investment in Vaxcyte, Inc. (NASDAQ:PCVX)

Mutual of America Capital Management LLC acquired a new position in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The fund acquired 48,330 shares of the company's stock, valued at approximately $3,035,000. Mutual of America Capital Management LLC owned about 0.05% of Vaxcyte as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. BlackRock Inc. increased its holdings in shares of Vaxcyte by 39.0% in the 2nd quarter. BlackRock Inc. now owns 7,065,088 shares of the company's stock valued at $352,830,000 after acquiring an additional 1,983,223 shares during the last quarter. Alliancebernstein L.P. increased its holdings in shares of Vaxcyte by 2,164.2% in the 2nd quarter. Alliancebernstein L.P. now owns 1,888,106 shares of the company's stock valued at $94,292,000 after acquiring an additional 1,804,718 shares during the last quarter. Westfield Capital Management Co. LP bought a new stake in shares of Vaxcyte in the 3rd quarter valued at approximately $51,180,000. Fred Alger Management LLC bought a new stake in shares of Vaxcyte in the 4th quarter valued at approximately $42,066,000. Finally, Franklin Resources Inc. grew its stake in Vaxcyte by 13,673.8% during the 1st quarter. Franklin Resources Inc. now owns 716,239 shares of the company's stock worth $26,845,000 after buying an additional 711,039 shares during the last quarter. 96.78% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts recently commented on the company. Cantor Fitzgerald restated an "overweight" rating on shares of Vaxcyte in a research note on Friday, January 12th. Bank of America upped their price objective on Vaxcyte from $67.00 to $80.00 and gave the stock a "buy" rating in a research note on Tuesday, January 2nd. Finally, Needham & Company LLC reiterated a "buy" rating and set a $95.00 price target on shares of Vaxcyte in a research report on Wednesday, April 10th. Four equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Vaxcyte has an average rating of "Buy" and a consensus target price of $78.50.

Vaxcyte Stock Up 0.3 %

PCVX stock traded up $0.21 during trading on Friday, reaching $60.83. 1,324,763 shares of the company's stock were exchanged, compared to its average volume of 839,504. Vaxcyte, Inc. has a 1-year low of $41.57 and a 1-year high of $82.04. The company's fifty day moving average price is $69.39 and its 200-day moving average price is $60.93. The firm has a market cap of $6.62 billion, a PE ratio of -14.73 and a beta of 0.89.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its quarterly earnings data on Tuesday, February 27th. The company reported ($1.82) earnings per share for the quarter, missing the consensus estimate of ($0.89) by ($0.93). During the same quarter last year, the business posted ($0.73) earnings per share. As a group, sell-side analysts expect that Vaxcyte, Inc. will post -4.18 earnings per share for the current fiscal year.

Insider Activity

In other news, SVP Mikhail Eydelman sold 1,667 shares of the company's stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $73.87, for a total value of $123,141.29. Following the completion of the sale, the senior vice president now owns 20,710 shares in the company, valued at $1,529,847.70. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other news, SVP Mikhail Eydelman sold 1,667 shares of the business's stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $73.87, for a total transaction of $123,141.29. Following the sale, the senior vice president now directly owns 20,710 shares of the company's stock, valued at $1,529,847.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Grant Pickering sold 2,616 shares of the business's stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $73.91, for a total value of $193,348.56. Following the sale, the chief executive officer now directly owns 149,978 shares in the company, valued at $11,084,873.98. The disclosure for this sale can be found here. Insiders sold a total of 101,577 shares of company stock worth $6,940,475 over the last 90 days. 3.60% of the stock is currently owned by company insiders.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.